FOXD1 and nasopharyngeal carcinoma: Drug sensitivity prediction analysis was performed using GDSC2 to predict the IC50 values of the FOXD1 high-expression group (high) and FOXD1 low-expression group (low), respectively, which showed that the drug sensitivity of GEM, the first-line chemotherapy drug for NPC treatment, was most negatively correlated with the expression of FOXD1 (Fig. 4A).